| BRCA1 | BRCA1 | BRCA1 | |||||
---|---|---|---|---|---|---|---|---|
Mutated | Non mutated | Unscreened | ||||||
Clinical characteristics | TN | Lum A | HER2+ | TN | TN | Lum A | Lum B | HER2+ |
Tumors analyzed, n | 23 | 7 | 2 | 21 | 15 | 20 | 22 | 21 |
Age, years, mean | 44 | 44 | 48 | 50 | 59 | 63 | 59 | 59 |
(range) | (28 to 60) | (29 to 71) | (42 to 54) | (28 to 72) | (31 to 83) | (43 to 86) | (37 to 85) | (34 to 84) |
Histology, n (%) | ||||||||
Ductal | 20 | 7 | 2 | 19 | 14 | 18 | 21 | 19 |
(87%) | (100%) | (100%) | (90%) | (93%) | (90%) | (69%) | (90%) | |
Lobular | 1 | 2 | 0 | 1 | 0 | 2 | 1 | 2 |
(4%) | (29%) | (0%) | (5%) | (0%) | (10%) | (5%) | (10%) | |
Metaplastic | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
(0%) | (0%) | (0%) | (5%) | (0%) | (0%) | (0%) | (0%) | |
Medullary | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
(8.7%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | |
Grade I | 0 | 0 | 0 | 1 | 0 | 12 | 1 | 3 |
(0%) | (0%) | (0%) | (5%) | (0%) | (60%) | (5%) | (14%) | |
Grade II | 0 | 3 | 0 | 3 | 3 | 7 | 9 | 9 |
(0%) | (43%) | (0%) | (14%) | (20%) | (35%) | (41%) | (43%) | |
Grade III | 23 | 4 | 2 | 17 | 12 | 1 | 12 | 9 |
(100%) | (57%) | (100%) | (81%) | (80%) | (5%) | (55%) | (43%) | |
Immunohistochemistry, n (%) | ||||||||
ER-positive, n (%) | 0 | 7 | 0 | 0 | 0 | 20 | 22 | 12 |
(0%) | (100%) | (0%) | (0%) | (0%) | (100%) | (100%) | (57%) | |
PR-positive, n (% | 0 | 5 | 0 | 0 | 0 | 20 | 22 | 12 |
(0%) | (71%) | (0%) | (0%) | (0%) | (100%) | (100%) | (57%) | |
HER2-positive, n (%) | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 21 |
(0%) | (0%) | (100%) | (0%) | (0%) | (0%) | (0%) | (100%) | |
KI67, mean, % | 42 | 7 | 47 | 35 | 48 | 7 | 44 | 34 |
P63- or EGFR- or CK14- or CK5/6-positive, n (%) | 11 | 1 | 1 | 7 | 9 | 0 | 1 | 3 |
(48%) | (14%) | (50%) | (33%) | (60%) | (0%) | (5%) | (14%) | |
Array CGH | ||||||||
Gain in 17q25.3, n (%) | 20 | 7 | 2 | 6 | 4 | 0 | 3 | 4 |
(87%) | (100%) | (100%) | (29%) | (27%) | (0%) | (14%) | (19%) |